Lester Sultatos completed his PhD in pharmacology at the Milton S. Hershey Medical School in Hershey, Pennsylvania, and received postdoctoral training in pharmacology and toxicology at the University of Texas Medical School at Houston in Houston. After 3 years as an assistant professor of pharmacology and experimental therapeutics at the Louisiana State University Medical School in New Orleans, he moved to the New Jersey Medical School in Newark, New Jersey, USA, where he is an associate professor in pharmacology and physiology.
MECHANISMS OF DRUGS THAT AFFECT UTERINE MOTILITY
Version of Record online: 31 DEC 2010
1997 American College of Nurse Midwives
Journal of Nurse-Midwifery
Volume 42, Issue 4, pages 367–370, July-August 1997
How to Cite
Sultatos, L. G. (1997), MECHANISMS OF DRUGS THAT AFFECT UTERINE MOTILITY. Journal of Nurse-Midwifery, 42: 367–370. doi: 10.1016/S0091-2182(97)60134-2
- Issue online: 31 DEC 2010
- Version of Record online: 31 DEC 2010
Modern obstetrics relies on a collection of drugs that affect the motility of the uterus either to stimulate or to suppress uterine contractions. Although a comprehensive, detailed understanding of how these drugs work does not yet exist, many, such as oxytocin, appear to work by altering cytosolic calcium levels in uterine smooth muscle cells. Other drugs, such as ritodrine, not only alter cytosolic calcium levels, but seem to inactivate myosin light chain kinase, a critical enzyme necessary for the initiation of uterine contractions. This report is intended to summarize the current state of knowledge regarding how these drugs affect the motility of the uterus. The delineation of the molecular mechanisms of action of these drugs is important because it provides the basis for their rational therapeutic use as well as for the design of new and better uterotrophic drugs.